PIM1 and hematologic disorder: Different studies could show selective activity of the pan‐PIM inhibitor AZD1208 in hematologic malignancies, such as Bellon and co‐workers who analyzed the effect of AZD1208 on Adult T‐cell leukemia (ATL) cells in vitro and showed induction of cell death in ATL cells, but not peripheral blood mononuclear cells (PBMCs) [6].